IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF WEST VIRGINIA

NOVO NORDISK INC. and NOVO NORDISK A/S,

Plaintiffs,

v.

C.A. No. 1:23-cv-13

VIATRIS INC. and MYLAN PHARMACEUTICALS INC.,

Defendant.

JOINT MOTION FOR EXTENSION

Plaintiffs Novo Nordisk Inc. and Novo Nordisk A/S, and Defendants Viatris Inc. and Mylan Pharmaceuticals Inc., by their undersigned counsel, hereby move the Court for an extension of the deadline to submit the Joint Report of Initial Planning Meeting that is currently due June 14, 2023 under the Court's Order Extending Deadlines dated May 18, 2023 (Dkt. No. 32).

While the parties appreciate that the Court previously denied a request for an extension of time (Dkt. 34), the parties have since appeared for a scheduling conference in the Delaware Wegovy Action, captioned *Novo Nordisk Inc. and Novo Nordisk A/S v. Viatris Inc. and Mylan Pharmaceuticals Inc.*, 1:23-cv-00101-CFC (D. Del.). The Delaware court ordered trial to proceed in the Delaware Wegovy Action in December 2024, and Defendants have represented that they intend to proceed in the Delaware Wegovy Action. A final schedule for the Delaware Wegovy Action is due to be submitted to the Delaware court on June 20, 2023. The parties are currently negotiating the dates for the final schedule in the Delaware Wegovy Action in view of the Delaware court's guidance at the Delaware Wegovy Action scheduling conference. Following entry of a final schedule in the Delaware Wegovy Action, the parties expect this West Virginia

Find authenticated court documents without watermarks at <u>docketalarm.com</u>.

We govy Action to be dismissed, avoiding the need for the Court to consider a schedule in this case.

Accordingly, to avoid burdening the Court and to avoid conflicting dates between the Delaware Wegovy Action and the West Virginia Wegovy Action, and in view the anticipated dismissal of this West Virginia Wegovy Action, the parties respectfully request that the date for submission of a Joint Report of Initial Planning Meeting that is currently due June 14, 2023 under the Court's Order Extending Deadlines dated May 18, 2023 (Dkt. No. 32) be extended to June 28, 2023.

Dated: June 14, 2023

Respectfully submitted,

SCHRADER COMPANION DUFF & LAW, PLLC

/s/ James F. Companion

James F. Companion (#790) Sandra K. Law (#6071) 401 Main Street Wheeling, WV 26003 (304) 233-3390 jfc@schraderlaw.com skl@schraderlaw.com

Δ

Attorneys for Plaintiffs, Novo Nordisk Inc and Novo Nordisk A/S

PERKINS COIE LLP

/s/ Brandon M. White Brandon M. White (WV Bar No. 14021) BMWhite@perkinscoie.com PERKINS COIE LLP 700 13th Street, NW, Suite 800 Washington, DC 20005 (202) 654-6200 bmwhite@perkincoie.com

Attorney for Defendants, Viatris Inc. and Mylan Pharmaceuticals Inc.